(C) Reuters. Point72 Asset Management established new holdings in Fulcrum Therapeutics, Inc.
On the 18th of September, Point72 Asset Management purchased 1.4 million Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shares for $12 million at an average price of $8.53 per share.
Shares of Fulcrum Therapeutics, Inc. are down -8.09% since the transaction.
Point72 Asset Management’s holding in Fulcrum Therapeutics, Inc. established a new holding of about 1.4 million shares with the purchase.
Point72 Asset Management first bought Fulcrum Therapeutics, Inc. stock in the second quarter of 2020.
Point72 Asset Management also owns Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Immunomedics Inc (NASDAQ:IMMU), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Arena Pharmaceuticals, Inc. (ARNA).
Fulcrum Therapeutics, Inc. is its number sixteen position by number of shares and market value among pharmaceuticals stocks.
Contrary to Point72 Asset Management, Millennium Management reduced FULC shares, while Victory Capital Management and Squarepoint Ops sold all their FULC shares.
Point72 Asset Management has also recently added to their share in Otonomy, Inc. (NASDAQ:OTIC).
The total value of the shares bought is estimated at around $8.9 million.
Point72 Asset Management also established new holdings in ANGI Homeservices Inc. (NASDAQ:ANGI) and Dave & Busters Entertainment Inc (PLAY).
Point72 Asset Management also added to their share in American Eagle Outfitters Inc (NYSE:AEO), The Children’s Place, Inc. (NASDAQ:PLCE), MacroGenics, Inc. (NASDAQ:MGNX), Bicycle Therapeutics plc (NASDAQ:BCYC) and Revolve Group , Inc. (NYSE:RVLV).
The total value of the shares bought is estimated at around $313 million.
Point72 Asset Management established new holdings in Fulcrum Therapeutics, Inc.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.